Abstract
Breast cancer stem cells are defined as cancer cells with self-renewal capacity. These cells represent a small subpopulation endowed with the ability to form new tumours when injected in nude mice. Markers of differentiation have been used to identify these cancer cells. In the case of breast cancer, CD44+/CD24− select a population with stem cell properties. The fact that these cells have self-renewal ability has suggested that this population could be responsible for new tumour formation and cancer relapse. These cells have been shown to be more resistant to chemotherapy and radiotherapy than normal cancer cells. The identification of the molecular druggable alterations responsible for the initiation and maintenance of cancer stem cells is an important goal. In this article we will review all these points with special emphasis on the possible role of new drugs designed to interact with molecular pathways of cancer stem cells.
Similar content being viewed by others
References
Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737
Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197: 461–463
Larochelle A, Vormoor J, Hanenberg H et al (1996) Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med 2:1329–1337
Reynolds BA, Weiss S (1992) Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255: 1707–1710
Davis AA, Temple S (1994) A self-renewing multipotential stem cell in embryonic rat cerebral cortex. Nature 372:263–266
Temple S (2001) The development of neural stem cells. Nature 414:112–117
Bassin RH, Plata EJ, Gerwin BI et al (1972) Isolation of a continuous epithelioid cell line, HBT-3, from a human breast carcinoma. Proc Soc Exp Biol Med 141:673–680
Whitehead RH, Bertoncello I, Webber LM, Pedersen JS (1983) A new human breast carcinoma cell line (PMC42) with stem cell characteristics. I. Morphologic characterization. J Natl Cancer Inst 70:649–661
Beier D, Hau P, Proescholdt M et al (2007) CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010–4015
Dalerba P, Dylla SJ, Park IK et al (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104:10158–10163
Gu G, Yuan J, Wills M, Kasper S (2007) Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67:4807–4815
Ho MM, Ng AV, Lam S, Hung JY (2007) Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67:4827–4833
Wang J, Guo LP, Chen LZ et al (2007) Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67:3716–3724
Smith GH, Medina D (1988) A morphologically distinct candidate for an epithelial stem cell in mouse mammary gland. J Cell Sci 90:173–183
Murphy KL, Dennis AP, Rosen JM (2000) A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J 14: 2291–2302
Xu X, Wagner KU, Larson D et al (1999) Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22:37–43
Al Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988
Herman PC, Huber SL, Herrier T et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323
Weissman I (2005) Stem cell research: paths to cancer therapies and regenerative medicine. JAMA 294:1359–1366
Ocana A, Hortobagyi GN, Esteva FJ (2006) Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer. Clin Breast Cancer 6:495–504
Hamilton A, Hortobagyi G (2005) Chemotherapy: what progress in the last 5 years? J Clin Oncol 23:1760–1775
Weinberg RA (2007) Using maths to tackle cancer. Nature 449:978–981
Marx J (2003) Cancer research. Mutant stem cells may seed cancer. Science 301:1308–1310
Bjerkvig R, Tysnes BB, Aboody KS et al (2005) Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 5:899–904
Qian X, Shen Q, Goderie SK et al (2000) Timing of CNS cell generation: a programmed sequence of neuron and glial cell production from isolated murine cortical stem cells. Neuron 28: 69–80
Setoguchi T, Taga T, Kondo T (2004) Cancer stem cells persist in many cancer cell lines. Cell Cycle 3:414–415
Kondo T, Setoguchi T, Taga T (2004) Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A 101:781–786
Uchida N, Buck DW, He D et al (2000) Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 97:14720–14725
Toren A, Bielorai B, Jacob-Hirsch J et al (2005) CD133-positive hematopoietic stem cell “stemness” genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells 23:1142–1153
Chiba T, Kita K, Zheng YW et al (2006) Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44:240–251
Collins AT, Berry PA, Hyde C et al (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951
Miki J, Furusato B, Li H et al (2007) Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67:3153–3161
Singh SK, Clarke ID, Terasaki M et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828
Yuan X, Curtin J, Xiong Y et al (2004) Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23:9392–9400
Liu G, Yuan X, Zeng Z et al (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67
Florek M, Haase M, Marzesco AM et al (2005) Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 319:15–26
O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110
Ricci-Vitiani L, Lombardi DG, Pilozzi E et al (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115
Barker N, van Es JH, Kuipers J et al (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449:1003–1007
Ponti D, Zaffaroni N, Capelli C, Daidone MG (2006) Breast cancer stem cells: an overview. Eur J Cancer 42:1219–1224
Clarke RB, Spence K, Anderson E et al (2005) A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol 277:443–456
Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58:267–284
Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21–33
Brabletz T, Jung A, Spaderna S et al (2005) Opinion: migrating cancer stem cells — an integrated concept of malignant tumour progression. Nat Rev Cancer 5:744–749
Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15:740–746
Balic M, Lin H, Young L et al (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12:5615–5621
Orimo A, Gupta PB, Sgroi DC et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335–348
Liu R, Wang X, Chen GY et al (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356:217–226
Massague J (2007) Sorting out breast-cancer gene signatures. N Engl J Med 356:294–297
Folkins C, Man S, Xu P et al (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67:3560–3564
Chang A, Li X, Wong H (2007) Therapeutic resistance and tumor-initiation: molecular pathways involved in breast cancer stem cell self-renewal. J Clin Oncol 25:528
Jiffar T, Kurinna S, Suck G et al (2004) PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. Leukemia 18:505–512
Szakacs G, Annereau JP, Lababidi S et al (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6:129–137
Hirschmann-Jax C, Foster AE, Wulf GG et al (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101:14228–14233
Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 98:1777–1785
Bao S, Wu Q, McLendon RE, et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760
Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5:341–354
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127–137
Massague J, Pandiella A (1993) Membrane-anchored growth factors. Annu. Rev. Biochem. 62:515–541
Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211–225
Doetsch F, Petreanu L, Caille I, et al (2002) EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells. Neuron 36:1021–1034
Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 23: 2445–2459
Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, et al (2006) PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form gliomalike growths in response to increased PDGF signaling. Neuron 51:187–199
Shipitsin M, Campbell LL, Argani P, et al (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11:259–273
Biswas S, Criswell TL, Wang SE, et al (2006) Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin. Cancer Res. 12:4142–4146
Bruna A, Darken RS, Rojo F, et al (2007) High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11:147–160
Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284:770–776
Bray SJ. 2006. Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell Biol. 7:678–689
Sun Y, Lowther W, Kato K, et al (2005) Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-beta signaling. Oncogene 24:5365–5374
Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, Eberhart CG. 2006. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 66:7445–7452
Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434:843–850
Liu S, Dontu G, Mantle ID, et al (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells 28. Cancer Res. 66:6063–6071
Ramirez-Castillejo C, Sanchez-Sanchez F, Andreu-Agullo C, et al (2006) Pigment epithelium-derived factor is a niche signal for neural stem cell renewal. Nat. Neurosci. 9:331–339
Notari L, Baladron V, Aroca-Aguilar JD et al (2006) Identification of a lipase-linked cell-membrane receptor for Pigment Epithelium-derived factor (PEDF). J. Biol. Chem. en revision
Gilbertson RJ, Rich JN (2007) Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 7:733–736
Miller K (2007) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium. Abstract 3
Ohno-Matsui K, Morita I, Tombran-Tink J, et al (2001) Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J. Cell Physiol 189:323–333.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by an unrestricted educational grant from Pfizer.
These three authors have contributed equally to this work.
Rights and permissions
About this article
Cite this article
García Bueno, J.M., Ocaña, A., Castro-García, P. et al. An update on the biology of cancer stem cells in breast cancer. Clin Transl Oncol 10, 786–793 (2008). https://doi.org/10.1007/s12094-008-0291-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-008-0291-9